Effect of Sacubitril-Valsartan on Cardiac Structure and Function in Adults With Congenital Heart Disease
Status: Recruiting
Location: See location...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Congenital Heart Disease Diagnosis
• Age 18 or Older
Locations
United States
Minnesota
Mayo Clinic in Rochester
RECRUITING
Rochester
Contact Information
Primary
Amanda Wozniak
Wozniak.Amanda@mayo.edu
507-266-1976
Time Frame
Start Date: 2025-02-03
Estimated Completion Date: 2026-12
Participants
Target number of participants: 45
Treatments
Experimental: Entresto
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: Mayo Clinic
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)